Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD)
Clinical Snapshot
Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are not two separate diseases but two points on a single, well-defined severity spectrum of the same underlying phenomenon: a cyclical, luteal-phase-restricted worsening of physical and emotional symptoms in ovulating individuals, followed by a genuinely symptom-free interval in the follicular phase.[1][2] PMDD is best understood as the specific, more severe, more emotionally predominant end of that spectrum — defined by its own explicit diagnostic symptom-count and functional-impairment threshold in the DSM-5-TR (see Recognize the Condition and Assessment & Diagnosis) — rather than as a wholly separate disorder.[2][3]
Some degree of premenstrual physical or mood change is close to universal: an estimated 70-90% of reproductive-aged women report at least some premenstrual discomfort.[2] About one-third of these have symptoms that meet the threshold for a PMS diagnosis; PMDD, the most severe form, has been reported in roughly 3-8% of women — but that figure drops sharply once the diagnosis is confirmed by prospective daily symptom charting rather than retrospective recall. A 2024 pooled analysis of 44 studies across more than 50,000 participants on 6 continents found a PMDD prevalence of 7.7% using a provisional, history-based diagnosis, compared with only 3.2% once confirmed with prospective daily symptom scoring — a genuinely large gap that underscores just how unreliable memory-based diagnosis is for this specific condition (see Assessment & Diagnosis).[2]
What actually drives it
Neither PMS nor PMDD is a disorder of abnormal hormone production. Serum estrogen and progesterone levels across the cycle in affected women are, on average, no different from those in unaffected women.[2] What differs is sensitivity: affected individuals appear to have an abnormal central nervous system response to the entirely normal fluctuation of reproductive hormones during the luteal phase.[2] Two mechanisms are most implicated. The first centres on allopregnanolone, a neuroactive metabolite of progesterone and a potent positive modulator of the GABA-A receptor — the late-luteal decline in progesterone (and, with it, allopregnanolone) is thought to trigger a disproportionate downstream effect on GABAergic inhibitory tone in susceptible individuals, even though absolute allopregnanolone levels themselves are typically normal.[2] The second implicates serotonergic dysfunction: women with PMS/PMDD show blunted serotonergic responsiveness specifically during the luteal phase and lower serotonin transporter density, and — most clinically telling — a consistent, often rapid symptomatic response to serotonin-enhancing therapy (see Choose Initial Treatment), which itself supports a genuine serotonergic contribution to the underlying mechanism rather than being merely coincidental.[2]
The defining timing pattern
Both conditions share the same non-negotiable timing signature: symptoms are confined to the luteal phase, characteristically emerging in the final one to two weeks before menses, and must resolve to a genuinely symptom-free interval by roughly cycle day 4 through ovulation.[1][2] A presentation that does not include this follicular-phase symptom-free window is not PMS or PMDD — it is either a different primary condition, or an existing psychiatric or medical condition that is being premenstrually exacerbated (PME — see Assessment & Diagnosis and Common Errors to Avoid), and treating it as PMDD without recognizing that distinction is a genuine, common diagnostic error.[1]
Recognize the Condition
Symptom domains
Both PMS and PMDD present with symptoms across three overlapping domains, though PMDD is defined by predominant, more severe affective symptoms specifically.[2]
- Affective/mood symptoms — irritability and anger (often the most impairing and most reported symptom in PMDD), depressed mood, tearfulness, anxiety and tension, mood lability with rapid, seemingly disproportionate shifts, a sense of being overwhelmed or out of control, and increased interpersonal conflict.[2][1]
- Behavioural/cognitive symptoms — difficulty concentrating, decreased interest in usual activities, lethargy and fatigue, changes in sleep (either insomnia or hypersomnia), and changes in appetite or specific food cravings.[2]
- Physical/somatic symptoms — breast tenderness and swelling, bloating, headache, joint or muscle pain, and a subjective sense of weight gain (often not a true weight change).[2][1]
The DSM-5-TR diagnostic pattern for PMDD — a genuinely defined threshold, not a subjective label
PMDD carries a specific, structured diagnostic threshold that separates it from milder PMS: at least 5 of the following 11 symptoms, with at least 1 drawn from the first 4 (the core affective symptoms), present in most menstrual cycles over the preceding year.[3][2]
| Symptom | What it looks like clinically |
|---|---|
| 1. Marked affective lability | Sudden mood swings, tearfulness, or a marked increase in sensitivity to rejection — a core affective symptom. |
| 2. Marked irritability, anger, or increased interpersonal conflict | Often the most disabling and most consistently reported single symptom — a core affective symptom. |
| 3. Markedly depressed mood, hopelessness, or self-deprecating thoughts | A core affective symptom; screen for suicidal ideation whenever present (see Red Flags & Refer). |
| 4. Marked anxiety, tension, or feeling "keyed up" or "on edge" | A core affective symptom. |
| 5. Decreased interest in usual activities | Work, school, friends, hobbies. |
| 6. Subjective difficulty concentrating | Patient-reported "brain fog," not necessarily confirmed on formal cognitive testing. |
| 7. Lethargy, easy fatigability, or marked lack of energy | |
| 8. Marked change in appetite, overeating, or specific food cravings | |
| 9. Hypersomnia or insomnia | |
| 10. A subjective sense of being overwhelmed or out of control | |
| 11. Physical symptoms | Breast tenderness or swelling, joint or muscle pain, a sensation of "bloating," or weight gain. |
Beyond the symptom count itself, four further criteria must all be met: the symptoms cause clinically significant distress or functional impairment (work, school, usual social activities, or relationships — see Assessment & Diagnosis); they are not merely an exacerbation of another disorder, though they may co-occur with one; they must be confirmed by prospective daily ratings across at least 2 consecutive symptomatic cycles, with a provisional diagnosis permitted before that confirmation is available; and they are not attributable to a substance, medication, or another medical condition.[3][2]
What separates PMDD from PMS
Both conditions share the identical luteal-restricted timing signature. What differs is severity, breadth, and threshold: the classic, still widely used ACOG working definition of PMS requires only one affective and one somatic symptom in the 5 days before menses, relieved within 4 days of menses onset and absent until at least cycle day 13, causing identifiable dysfunction.[1] PMDD requires the specific 5-of-11, core-affective-symptom-anchored DSM-5-TR threshold above, with correspondingly greater functional impairment. In practical terms: PMS is common, often milder, and frequently responds to lifestyle measures alone; PMDD is the genuinely disabling, emotionally predominant end of the same spectrum that generally needs pharmacotherapy (see Choose Initial Treatment).[1][2]
Trajectory over the reproductive lifespan
Because both conditions require ovulatory cycling, they are — by definition — absent before menarche, suppressed during pregnancy and lactational amenorrhea, and can worsen substantially during the perimenopausal transition as cycles become more hormonally erratic, before resolving after natural or surgical menopause (see Special Populations).[1]
Risk Factors
- A personal or family history of PMS/PMDD — twin and family studies support a genuine heritable component to hormone sensitivity.[2]
- A personal history of major depressive disorder, an anxiety disorder, or postpartum depression — strongly associated, and the relationship appears bidirectional rather than PMDD simply being a subtype of these conditions; a history of PMDD is itself a recognized risk factor for postpartum and perimenopausal depression.[2]
- A history of psychological trauma, including sexual trauma — associated with a higher risk of PMDD specifically.[2]
- Cigarette smoking and obesity — both are independently associated with more severe premenstrual symptoms.[1]
- Perimenopausal-transition-related hormonal variability — cycle-to-cycle hormone fluctuation becomes more erratic in the years before menopause, and symptoms often worsen during this window before resolving after menopause (see Special Populations).[1]
- High life stress and low social support — both correlate with greater symptom severity, though the direction of causality is not fully established.[2]
- Low dietary calcium intake — observational data link lower calcium status to greater PMS symptom burden, part of the rationale for calcium supplementation as treatment (see Non-Pharmacologic Treatment).[2]
Red Flags & Refer
The following change the plan from routine premenstrual-symptom management to urgent escalation or reconsideration of the diagnosis itself:
- Any suicidal ideation, a specific plan, or a prior suicide attempt. This is not a rare complication of PMDD — more than 15% of affected individuals report a lifetime suicide attempt, and PMDD carries roughly 4 times greater odds of suicidal ideation and roughly 7 times greater odds of a suicide attempt compared with those without the disorder.[2] Screen directly and explicitly at every encounter where mood symptoms are discussed, and treat any positive response as an emergency requiring immediate escalation, not something to revisit at the next visit.[2]
- Symptoms present throughout the cycle, with no genuine follicular-phase symptom-free window. This is not PMDD — it is either premenstrual exacerbation (PME) of an underlying psychiatric condition (major depressive disorder, an anxiety disorder, bipolar disorder) or a different primary diagnosis, and requires a full psychiatric assessment rather than PMDD-specific treatment alone (see Assessment & Diagnosis and Common Errors to Avoid).[1]
- Any history or current symptoms suggesting bipolar disorder — elevated/expansive mood, decreased need for sleep without fatigue, grandiosity. Treating unrecognized bipolar disorder with an SSRI alone risks precipitating a manic or hypomanic episode; refer for psychiatric assessment before starting antidepressant therapy if this is suspected.[2]
- No genuine symptom-free interval ever established despite adequate prospective charting — reconsider the diagnosis entirely rather than continuing to escalate PMDD-specific treatment.[1]
- Inadequate response despite an adequate trial of first-line pharmacotherapy — reassess the diagnosis, screen for a missed comorbidity, and consider referral to gynecology or psychiatry rather than continuing to cycle through agents indefinitely (see Treatment Failure/Next Step).[1]
- New or escalating symptoms specifically during the perimenopausal transition — the erratic hormonal pattern of perimenopause can both worsen underlying PMDD and mimic it with a new, non-cyclical mood or vasomotor picture; reassess the timing pattern carefully rather than assuming continuity of a prior diagnosis (see Special Populations).[1]
Assessment & Diagnosis
Why retrospective recall is not enough
The single most important — and most frequently skipped — step in diagnosing either PMS or PMDD is prospective, not retrospective, symptom documentation. Patient recall of symptom timing is genuinely unreliable: the 2024 pooled analysis referenced in Clinical Snapshot found a PMDD prevalence of 7.7% using a provisional, history-based diagnosis compared with only 3.2% once confirmed with prospective daily symptom scoring — more than a two-fold difference driven entirely by the unreliability of memory-based reporting of cyclical symptom timing.[2] Patients — and clinicians relying on a single retrospective interview — systematically overattribute symptoms to the premenstrual window and underrecognize a genuine follicular-phase symptom-free interval, especially when an underlying mood or anxiety disorder is also present (see Common Errors to Avoid).[1][2]
How to chart prospectively
Have the patient complete a validated daily rating instrument — the Daily Record of Severity of Problems (DRSP) or the Calendar of Premenstrual Experiences (COPE) are the most widely used — across at least 2 consecutive symptomatic menstrual cycles, rating each relevant symptom's severity daily regardless of cycle day.[1][3] A clinician may reasonably make a provisional diagnosis and start empiric treatment while charting is underway, given the real-world impracticality of asking a significantly symptomatic patient to simply wait 2 more months — but the diagnosis should be treated as provisional, and confirmed or revised once the charting data is available, rather than assumed to be settled from the first visit.[3][1] On review, look specifically for the defining pattern: symptom onset in the final 1-2 weeks of the luteal phase, improvement within a few days of menses onset, and a genuinely symptom-free (or near-symptom-free) interval from roughly cycle day 4 through ovulation. Symptoms that persist, even at lower intensity, through the follicular phase point away from primary PMS/PMDD and toward PME of an underlying condition instead (see below and Red Flags & Refer).[1]
Diagnostic criteria side by side
| PMS | PMDD | |
|---|---|---|
| Symptom threshold | At least 1 affective and 1 somatic symptom | At least 5 of 11 defined symptoms, including at least 1 core affective symptom (see Recognize the Condition) |
| Timing | Present in the 5 days before menses, relieved within 4 days of menses onset, absent until at least cycle day 13 | Present in the final week before menses, improving within a few days of menses onset, minimal/absent in the week postmenses |
| Confirmation | Reproducible over at least 2 cycles of prospective recording | Confirmed by prospective daily ratings over at least 2 consecutive symptomatic cycles |
| Impact | Identifiable dysfunction in social or occupational performance | Clinically significant distress or functional impairment in social, occupational, or relational functioning |
| Character | Physical and/or emotional symptoms of variable predominance | Predominantly, severely affective — irritability, depressed mood, anxiety, or lability specifically required |
The essential differential: premenstrual exacerbation (PME)
Many psychiatric and medical conditions — major depressive disorder, generalized anxiety disorder, bipolar disorder, migraine, irritable bowel syndrome, seizure disorders — genuinely do worsen premenstrually. This is premenstrual exacerbation (PME), not PMDD, and the distinction matters clinically: PME implies an underlying condition requiring its own full assessment and treatment, on top of which the premenstrual worsening should be addressed, rather than a stand-alone PMDD diagnosis and PMDD-specific treatment alone.[1][2] The key differentiator on prospective charting is the follicular-phase pattern: true PMDD requires a genuinely symptom-free interval; PME shows a baseline level of symptoms throughout the cycle that simply intensifies premenstrually.[1]
Laboratory and other testing
There is no diagnostic laboratory test for PMS or PMDD — serum hormone levels are not useful diagnostically, since the disorder reflects abnormal sensitivity to normal hormone fluctuation rather than an abnormal hormone level itself (see Clinical Snapshot).[2] A thyroid-stimulating hormone level is reasonable to obtain at initial assessment, since hypothyroidism can mimic several PMDD symptoms (fatigue, mood change, weight change) without the defining cyclical pattern; beyond this, testing should be directed by the differential rather than ordered routinely.[2]
Treatment Targets
- Confirm the diagnosis with prospective charting before committing to a long-term treatment plan, since an accurate diagnosis is itself the foundation of appropriate treatment selection (see Assessment & Diagnosis).[1]
- Reduce the severity of luteal-phase affective, behavioural, and physical symptoms, with particular priority on the affective symptoms that drive most of PMDD's functional impairment.[2]
- Restore social, occupational, and relational functioning — the explicit functional-impairment criterion in the diagnosis itself (see Recognize the Condition) — not merely reduce a symptom score in isolation.[3]
- Match treatment intensity to genuine severity: lifestyle measures alone for milder PMS, pharmacotherapy for PMDD or functionally impairing PMS, and escalation reserved for a demonstrated inadequate response to an adequate trial (see Choose Initial Treatment).[1]
- Screen for and address suicidal ideation at every visit where mood symptoms are the presenting concern, regardless of how the rest of treatment is progressing (see Red Flags & Refer).[2]
- Where contraception is also desired, consider whether a single agent — a drospirenone-containing combined oral contraceptive — can reasonably serve both goals (see Pharmacologic Treatment Options).[4]
Choose Initial Treatment
Match treatment to confirmed severity — lifestyle first for milder PMS, SSRIs first-line for PMDD
Mild-to-moderate PMS, minimal functional impairment start with lifestyle measures — exercise, calcium ± vitamin B6 supplementation, and cognitive behavioural therapy — as reasonable, evidence-supported first-line options (see Non-Pharmacologic Treatment).[1] PMDD, or PMS with genuine functional impairment an SSRI is first-line pharmacotherapy — and a genuinely distinctive option specific to this condition is that it can be dosed only during the luteal phase rather than continuously, unlike essentially every other SSRI indication (see below).[1][2] Wants combined hormonal contraception, or physical symptoms predominate a drospirenone-containing combined oral contraceptive is a reasonable alternative or adjunct.[4] Severe, refractory to the above a GnRH agonist with add-back therapy is the next escalation, reserved specifically for confirmed, severe, treatment-refractory PMDD (see below and Treatment Failure/Next Step).[1][2]
SSRIs — first-line pharmacotherapy, with a genuinely distinctive dosing option
SSRIs are first-line pharmacotherapy for moderate-to-severe PMDD, and their effect in this specific condition is not simply "treating comorbid depression" — SSRIs and other serotonin-enhancing agents consistently reduce premenstrual symptoms even in patients without any comorbid depressive or anxiety disorder, supporting a genuine, condition-specific serotonergic mechanism.[2] Sertraline, paroxetine (including the controlled-release formulation), and fluoxetine carry the most robust trial evidence and FDA approval specifically for PMDD; citalopram, escitalopram, and the SNRI venlafaxine are reasonable, effective alternatives without a PMDD-specific approval.[2][1]
The high-yield, non-obvious point unlike essentially every other indication for an SSRI, the effect in PMS/PMDD is genuinely rapid — often within days rather than the several weeks typically needed for an antidepressant effect in major depressive disorder — which makes luteal-phase-only (intermittent) dosing a real, evidence-supported option, not merely a theoretical one.[2][1] A patient may take the same SSRI either continuously (every day, all cycle) or intermittently — starting the medication at ovulation (roughly day 14 of a 28-day cycle, or a fixed number of days before the next expected menses) and stopping once menses begins — with equivalent efficacy demonstrated between the two strategies and no evidence that continuous dosing outperforms luteal-phase-only dosing.[1][2] For a patient with a very predictable, short symptomatic window, dosing that starts only at the onset of symptoms themselves is a further, even more restricted variant of the same intermittent approach.[1]
Choice of SSRI for intermittent dosing should account for pharmacokinetics: sertraline's intermediate half-life makes it a common practical choice for luteal-phase-only dosing, fluoxetine's long half-life is genuinely forgiving of an imprecise start/stop schedule but may take longer to reach and clear steady state, and paroxetine's short half-life among the SSRIs means abrupt stop/start with intermittent dosing carries a real, and often underappreciated, discontinuation-symptom risk that should be discussed with the patient in advance (see Common Errors to Avoid).[2]
Nausea is the most common adverse effect and typically resolves within the first several days of each restart, including with intermittent dosing; reduced libido and anorgasmia can occur but generally resolve during the medication-free follicular-phase interval on an intermittent regimen — itself a genuine advantage of luteal-phase dosing for a patient bothered by sexual side effects on continuous therapy.[2] If an initial SSRI provides inadequate relief after an adequate trial, switching to an alternative SSRI (or to venlafaxine) is a reasonable next step before escalating further (see Treatment Failure/Next Step).[2]
Combined oral contraceptives — drospirenone-containing specifically
Standard combined oral contraceptives improve the physical manifestations of premenstrual disorders (breast tenderness, bloating, menstrual pain) more reliably than mood symptoms, and some formulations can actually worsen mood during the pill-free interval.[2] Drospirenone-containing combined oral contraceptives are a genuine exception: drospirenone's anti-mineralocorticoid and anti-androgenic pharmacology gives it a distinct evidence base from other progestins for this specific indication, and a drospirenone/ethinyl estradiol formulation dosed on a 24-active/4-placebo-day schedule is FDA-approved specifically for PMDD in women who also desire contraception.[4] A 2023 Cochrane review of 5 randomized trials (858 women, predominantly with PMDD) found drospirenone/ethinyl estradiol produced a small-to-moderate improvement in overall premenstrual symptoms and functional impairment (productivity, social activities, relationship interference) compared with placebo, though the certainty of evidence was rated low-to-very-low, adverse-effect-related trial withdrawal was significantly increased (breast pain, nausea, and intermenstrual bleeding in particular), placebo response was substantial, and no trial compared drospirenone-containing formulations directly against other combined oral contraceptives or against SSRIs.[4] Given the residual hormone-free-interval symptom risk with any cyclic COC, an extended or continuous-dosing regimen (minimizing or eliminating the placebo interval) is a reasonable way to reduce that specific problem.[1]
GnRH agonists with add-back therapy — "medical oophorectomy" for severe, refractory PMDD
For confirmed, severe PMDD that has not responded to an adequate trial of SSRIs (including a switch between agents) and/or a drospirenone-containing COC, a GnRH agonist — leuprolide or goserelin — is a genuinely effective next step, working by suppressing ovarian hormone production entirely and inducing a temporary medical menopause; because ovulatory cycling is required to drive PMDD, eliminating the cycle reliably eliminates the symptoms in appropriately selected patients.[2][1] Do not use unopposed beyond ~6 months without add-back therapy, given the otherwise substantial risk of vasomotor symptoms, bone mineral density loss, and other hypoestrogenic effects of an induced medical menopause.[1][2] Add-back therapy — low-dose continuous combined estrogen-progestin (for example, transdermal estradiol with norethindrone acetate, or low-dose oral conjugated estrogen with a progestin) — is added specifically to blunt these hypoestrogenic effects while generally preserving the GnRH agonist's PMDD benefit, and allows longer-term use with appropriate monitoring (see Monitoring & Follow-Up).[1][2] A minority of patients do experience some recurrence of PMDD-type symptoms once add-back is started, which should prompt a frank discussion of the trade-off rather than automatic discontinuation of add-back.[2] Given cost, injection burden, and the hypoestrogenic risk profile, GnRH agonist therapy is reserved specifically for confirmed, severe, refractory disease — not used as an earlier-line option.[1]
Surgical menopause — the genuine last resort
Bilateral salpingo-oophorectomy, generally combined with hysterectomy, is reserved for the rare patient with severe, genuinely refractory, and significantly impairing PMDD (including a history of PMDD-related suicidal ideation) who has demonstrated a clear symptomatic response to a GnRH agonist trial — that trial response is itself used as a predictor of surgical benefit before committing to an irreversible procedure.[2] Estrogen-only hormone therapy is typically needed after surgical menopause, particularly in a younger patient, to manage the consequences of premature surgical menopause; the specific regimen should be individualized with gynecology.[2]
Non-Pharmacologic Treatment
Exercise
Regular moderate exercise — aerobic activity, yoga, or Pilates — is associated with improvement in premenstrual symptoms, plausibly through increased beta-endorphin activity, and is recommended by ACOG as first-line for milder PMS; the supporting evidence is of low quality (drawn mostly from non-randomized studies) but the intervention itself carries essentially no downside, which supports recommending it broadly regardless of severity.[1]
Calcium supplementation — the best-evidenced supplement
Calcium metabolism fluctuates across the menstrual cycle, and lower calcium status has been observed in women with PMS. In randomized trial data, calcium supplementation at 1200 mg/day significantly reduced symptom severity, and it is the supplement with the strongest evidence base and an explicit ACOG recommendation among all those studied for this indication.[1][2]
Vitamin B6 (pyridoxine)
Vitamin B6 supplementation is recommended by several bodies (including the Royal College of Obstetricians and Gynaecologists) despite genuinely inconclusive trial-level evidence — it is a reasonable, low-risk adjunct rather than a strongly evidence-backed intervention in its own right.[2] Cap the dose doses above roughly 100 mg/day are not recommended, given a real risk of peripheral sensory neuropathy with prolonged high-dose use — a genuinely important, easily overlooked counselling point given vitamin B6's over-the-counter availability and reputation as "just a vitamin."
Cognitive behavioural therapy
CBT — incorporating psychoeducation, cognitive restructuring, relaxation techniques, and stress-management strategies specifically targeted to the premenstrual symptom pattern — has demonstrated effectiveness comparable to antidepressant medication in meta-analysis, making it a genuine first-line option in its own right, not merely an adjunct to pharmacotherapy.[1]
Other measures with weaker or more limited evidence
- Vitamin D — several studies suggest a potential benefit, though evidence remains less robust than for calcium.[2]
- Dietary modification — reducing caffeine, sodium, and alcohol intake is commonly advised and low-risk, though direct trial evidence specifically supporting it is limited.
- Chasteberry (Vitex agnus-castus) — low-to-moderate-quality randomized trials suggest some benefit, but ACOG does not recommend routine use given substantial variability in formulation and dosing across studies and products, which makes counselling on a specific, reliable product genuinely difficult.[1]
- Acupuncture — low-quality evidence suggests possible benefit for both mood and physical symptoms; ACOG supports considering it given the combination of potential benefit and low risk of harm.[1]
- Insufficient current evidence supports routine supplementation with iron, zinc, or other B vitamins specifically for this indication.[2]
Special Populations
Adolescents
PMDD can be diagnosed in adolescents using the same DSM-5-TR criteria, though prospective charting can be genuinely harder to sustain in this age group — engage the patient directly in the charting process rather than relying solely on a parent's report. Lifestyle measures and CBT are reasonable first steps; SSRI use follows the same evidence base as in adults, with the same general antidepressant safety considerations relevant to this age group applied.[2]
The perimenopausal transition
Cycle-to-cycle hormonal variability increases substantially in the years before menopause, and established PMDD frequently worsens during this transition before resolving after natural menopause, since ovulatory cycling is required to sustain the disorder.[1] Distinguishing a genuine worsening of established PMDD from an emerging, non-cyclical perimenopausal mood or vasomotor picture requires the same prospective-charting approach used at initial diagnosis — do not assume continuity of a prior diagnosis without re-confirming the cyclical pattern is still present (see Red Flags & Refer).[1]
Pregnancy and postpartum
PMS and PMDD are, by definition, suppressed during pregnancy and lactational amenorrhea, since both require ovulatory cycling. A patient with an established SSRI regimen for PMDD who becomes pregnant needs an individualized continue-versus-taper discussion consistent with general antidepressant-in-pregnancy principles, rather than an automatic assumption that the indication has simply disappeared for the duration of pregnancy. A history of PMDD is itself a recognized risk factor for postpartum depression, and screening should be proactive rather than reactive in this population.[2]
Renal impairment, and concurrent ACE inhibitor/ARB/potassium-sparing diuretic use
Drospirenone's anti-mineralocorticoid activity carries a genuine hyperkalemia risk in a patient with renal impairment or concurrent use of an ACE inhibitor, angiotensin receptor blocker, potassium-sparing diuretic, or chronic NSAID use — favour a non-drospirenone option or monitor potassium closely if a drospirenone-containing product is still used in this setting (see Common Errors to Avoid).
Comorbid psychiatric illness
A patient with an existing depressive, anxiety, or bipolar disorder needs the PME distinction actively revisited (see Assessment & Diagnosis) — treating a premenstrual exacerbation of an inadequately controlled underlying disorder as if it were primary PMDD, without also optimizing treatment of the underlying condition itself, is a genuine and avoidable source of treatment failure.[1]
Breastfeeding
Sertraline is generally considered a preferred SSRI choice during breastfeeding given its favourable relative infant dose profile among the SSRIs, consistent with general perinatal psychiatric prescribing principles; confirm current guidance for the specific agent and clinical context before continuing or starting therapy while breastfeeding.
Monitoring & Follow-Up
- Continue prospective daily symptom charting through at least the first 2-3 treatment cycles to objectively confirm response, rather than relying on the patient's retrospective global impression alone — the same unreliability that affects diagnosis affects self-assessed treatment response.[1][2]
- Reassess an SSRI trial for adequacy at 2-3 cycles before concluding it has failed, given the intermittent-dosing option's own cycle-to-cycle variability.[1]
- Screen explicitly for suicidal ideation at every visit where mood symptoms are the presenting concern, throughout treatment, not only at initial diagnosis (see Red Flags & Refer).[2]
- On a drospirenone-containing COC in a patient with a relevant risk factor (renal impairment, ACE inhibitor/ARB use, chronic NSAID use): check potassium after the first cycle and periodically thereafter.
- On a GnRH agonist: obtain a baseline bone mineral density measurement before starting if therapy beyond 6 months is anticipated, add estrogen-progestin add-back therapy by that point if not already started, and reassess bone density periodically with continued use; monitor for vasomotor symptoms and osteoporosis risk factors at each visit.[1][2]
- Reassess the diagnosis itself — not just the treatment — if response remains inadequate despite an adequate trial at each step, since an incorrect diagnosis (most often unrecognized PME) is a genuine and common reason for apparent treatment failure (see Common Errors to Avoid).[1]
Common Errors to Avoid
- Diagnosing PMS or PMDD from a single retrospective interview rather than confirming the diagnosis with prospective daily charting across at least 2 cycles — retrospective recall roughly doubles apparent prevalence compared with confirmed, prospectively-charted diagnosis.[2]
- Missing premenstrual exacerbation (PME) of an underlying psychiatric disorder — treating it as primary PMDD without a full psychiatric assessment, and without recognizing that PME requires optimizing treatment of the underlying condition itself, not just premenstrual-specific therapy.[1]
- Telling a patient starting an SSRI for PMDD to expect the same several-week delayed onset used for major depressive disorder counselling — PMDD's SSRI response is typically rapid, within days, and this is exactly what makes luteal-phase-only dosing a genuine option worth actively offering, not a detail to omit.[2][1]
- Starting or stopping paroxetine abruptly on an intermittent luteal-phase schedule without counselling on its comparatively high discontinuation-symptom risk given its short half-life among the SSRIs used for this indication.[2]
- Recommending vitamin B6 without a dose ceiling — doses above roughly 100 mg/day carry a real peripheral neuropathy risk with prolonged use, and this is easy to miss given the supplement's over-the-counter, "harmless vitamin" reputation.
- Continuing a GnRH agonist beyond about 6 months without add-back therapy, or without a baseline and follow-up bone mineral density plan.[1][2]
- Prescribing a drospirenone-containing combined oral contraceptive without considering hyperkalemia risk in a patient with renal impairment or concurrent ACE inhibitor/ARB/potassium-sparing diuretic use.
- Not screening explicitly for suicidal ideation because the presenting complaint is framed as "just PMS" — PMDD carries a genuinely elevated suicide risk that is easy to underweight when the diagnosis sounds mild.[2]
- Assuming any combined oral contraceptive will reliably improve mood symptoms — most COCs are more reliable for physical symptoms than for the affective symptoms that define PMDD, and a cyclic (non-extended) regimen can worsen mood specifically during the hormone-free interval.[2]
- Escalating through pharmacologic steps indefinitely without reassessing whether the original diagnosis — and specifically the follicular-phase symptom-free interval — was ever actually confirmed.[1]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Selective Serotonin Reuptake Inhibitors / SNRI
First-line pharmacotherapy for PMDD and functionally impairing PMS. Uniquely for this indication, response is typically rapid (days), which supports dosing continuously all cycle or intermittently during the luteal phase only, with equivalent demonstrated efficacy between the two strategies.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Sertraline | Continuous: 50-150 mg/day Luteal-phase-only: 50-100 mg/day, started at ovulation (~day 14) through the first 1-3 days of menses | Nausea, reduced libido/anorgasmia, headache, insomnia — nausea typically resolves within days of each restart on an intermittent regimen | Serotonin syndrome risk with other serotonergic agents (MAOIs, triptans, other SSRIs/SNRIs, tramadol); numerous CYP-mediated interactions | Intermediate half-life makes it a common practical first choice for luteal-phase-only dosing |
| Fluoxetine | Continuous or luteal-phase-only: 20-60 mg/day | Nausea, insomnia, sexual dysfunction, early activation/anxiety | Serotonin syndrome risk with other serotonergic agents; strong CYP2D6 inhibitor — review the full medication list before starting | FDA-approved specifically for PMDD. Long half-life is forgiving of an imprecise luteal-phase start/stop schedule but slower to reach and clear steady state |
| Paroxetine | Continuous or luteal-phase-only: 12.5-25 mg/day controlled-release, or an equivalent immediate-release dose | Nausea, sedation, sexual dysfunction, anticholinergic effects | Serotonin syndrome risk with other serotonergic agents; strong CYP2D6 inhibitor | FDA-approved specifically for PMDD (including the controlled-release formulation). Shortest half-life among these SSRIs — counsel specifically on discontinuation symptoms with abrupt intermittent stop/start |
| Escitalopram | Continuous or luteal-phase-only: Per product monograph, titrated to response | Nausea, headache, sexual dysfunction | Serotonin syndrome risk with other serotonergic agents | Effective alternative without a PMDD-specific regulatory approval; reasonable after an inadequate first SSRI trial |
| Citalopram | Continuous or luteal-phase-only: Per product monograph, titrated to response | Nausea, headache, dose-dependent QT-interval prolongation | Serotonin syndrome risk with other serotonergic agents; avoid combining with other QT-prolonging drugs at higher doses | Effective alternative without a PMDD-specific regulatory approval; consider baseline QT risk factors at higher doses |
| Venlafaxine | Continuous or luteal-phase-only: Per product monograph, titrated to response | Nausea, elevated blood pressure at higher doses, discontinuation symptoms with missed doses | Serotonin syndrome risk with other serotonergic agents; avoid with MAOIs | SNRI alternative for inadequate response to an SSRI trial; reasonable step before escalating to a GnRH agonist |
Combined Hormonal Contraceptive
Standard COCs improve physical symptoms more reliably than mood; drospirenone-containing formulations have a distinct, PMDD-specific evidence base given their anti-mineralocorticoid/anti-androgenic pharmacology.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Drospirenone / Ethinyl Estradiol | Standard regimen: 24 days active / 4 days placebo per product monograph | Breast pain, nausea, intermenstrual bleeding, hyperkalemia (anti-mineralocorticoid activity), standard COC VTE risk | Additive hyperkalemia risk with ACE inhibitors, ARBs, potassium-sparing diuretics, or chronic NSAID use; standard COC drug-interaction cautions apply | The FDA-approved 24-active/4-placebo-day regimen has the most direct PMDD trial evidence among combined oral contraceptives (2023 Cochrane review: small-to-moderate benefit, low-certainty evidence, increased adverse-effect withdrawal). Extended/continuous-cycle use reduces hormone-free-interval symptom recurrence |
Non-Pharmacologic Adjunct Supplements
Reasonable first-line options for milder PMS, and a reasonable adjunct to pharmacotherapy at any severity.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Calcium Carbonate | Daily dose: 1200 mg/day elemental calcium | Constipation, bloating at higher doses | May reduce absorption of certain oral medications (e.g., some antibiotics, bisphosphonates, thyroid hormone) if taken simultaneously — space administration | The best-evidenced single supplement studied for this indication |
| Pyridoxine (Vitamin B6) | Daily dose: Up to approximately 100 mg/day | Peripheral sensory neuropathy with prolonged high-dose use above the recommended ceiling | None significant at recommended doses | Recommended despite inconclusive trial-level evidence; counsel explicitly on the dose ceiling |
Adjunctive Anxiolytic — Reserved, Second-Line
Not a routine or first-line option; reserve for selected patients with severe premenstrual anxiety or insomnia given real dependence risk.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Alprazolam | If used: Lowest effective dose per product monograph, luteal-phase-limited | Dependence and withdrawal risk, sedation, additive CNS depression | Additive CNS/respiratory depression with opioids, alcohol, or other sedatives; avoid combining with other benzodiazepines | Use the lowest effective dose, limited to the luteal phase, with close monitoring — particularly in a patient with any history of substance use |
GnRH Agonists — Severe, Refractory PMDD
Reserved for confirmed, severe PMDD refractory to SSRI and/or drospirenone-containing COC trials. Add-back therapy is required beyond approximately 6 months of use to limit hypoestrogenic bone and vasomotor effects.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Leuprolide acetate | Dosing: Per product-specific depot monograph | Hot flashes, bone mineral density loss without add-back, initial hormonal flare, injection-site reactions | None significant | Depot formulation, typically monthly or every 3 months. Symptom response predicts benefit from eventual bilateral salpingo-oophorectomy in refractory cases |
| Goserelin | Dosing: Per product-specific depot monograph | Same class effects as leuprolide | None significant | Depot implant, typically every 4 or 12 weeks — an alternative brand/formulation within the same class, same role and monitoring requirements |
NSAIDs for Physical/Somatic Symptoms
Targets premenstrual physical symptoms (headache, joint/muscle pain, dysmenorrhea) specifically; does not address the affective symptoms that drive most PMDD-related functional impairment.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Naproxen | Adults: Per product monograph | Standard NSAID gastrointestinal, renal, and cardiovascular risks | Additive bleeding risk with anticoagulants; avoid combining with other NSAIDs | Taken as needed during the symptomatic window |
| Ibuprofen | Adults: Per product monograph | Standard NSAID gastrointestinal, renal, and cardiovascular risks | Additive bleeding risk with anticoagulants; avoid combining with other NSAIDs | Taken as needed during the symptomatic window |
| Mefenamic Acid | Adults: Per product monograph | Standard NSAID gastrointestinal, renal, and cardiovascular risks; diarrhea | Additive bleeding risk with anticoagulants; avoid combining with other NSAIDs | An alternative NSAID with specific trial evidence in dysmenorrhea/menstrual pain |
References
- Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No. 7 — American College of Obstetricians and Gynecologists. Obstet Gynecol 2023;142(6):1516-1533
- Premenstrual Disorders — StatPearls Publishing (Miller C, Carlson K). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; last updated August 9, 2026
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) — American Psychiatric Association. Washington (DC): American Psychiatric Publishing; 2022
- Oral contraceptives containing drospirenone for premenstrual syndrome — Cochrane Database of Systematic Reviews (Ma S, Song SJ). Cochrane Database Syst Rev 2023;2023(6):CD006586
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.